Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186822 | 0.79 | CYP4F2 (0.49) | CYP4F2CYP4A11THRBPKM | |
| SCHEMBL187373 | 0.78 | CYP4F2 (0.51) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL187214 | 0.71 | CYP4F2 (0.51) | CYP4F2CYP4A11 | |
| SCHEMBL186940 | 0.70 | CYP4F2 (0.65) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL187126 | 0.70 | CYP4F2 (0.53) | CYP4F2CYP4A11MAPTKMT2A | |
| SCHEMBL27898588 | 0.67 | MEN1 (0.53) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL21214454 | 0.67 | MEN1 (0.57) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL18380792 | 0.67 | MEN1 (0.57) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL18909478 | 0.67 | MEN1 (0.57) | CYP4F2CYP4A11MEN1MAPTKMT2A | |
| SCHEMBL3279511 | 0.67 | CYP4F2 (0.52) | CYP4F2CYP4A11MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067466-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | PNLIP, NR1H3, NR1H2 | CYP4F2 713/4885CYP4A11 91/4885MEN1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.